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Purpose: To analyze the 24-hour ocular dimensional profile in normal-tension glaucoma (NTG) 
patients on medical treatment.
Methods: Consecutive, medically treated NTG subjects were recruited from a university eye 
center. Subjects were on a mean of 1.7±0.7 types of antiglaucoma medications and 56.6% were 
on a prostaglandin analog. A contact lens-based sensor device was worn in one eye of NTG 
patients to record the intraocular pressure (IOP)-related profile for 24 hours, recording the fol-
lowing: variability from mean over 24 hours, nocturnally and diurnally, as well as the number 
of peaks and troughs diurnally and nocturnally.
Results: In 18 NTG subjects, the nocturnal variability around the mean contact lens-based 
sensor device signal was 48.9% less than the diurnal variability around the mean. The number 
of peaks was 54.7% less during the nocturnal period than during the diurnal period. The rate 
of increase in the ocular dimensional profile when going to sleep was significantly greater than 
the rate of decrease upon waking (P0.001).
Conclusion: In medically treated NTG subjects, there was more variability in the IOP-related 
pattern during the daytime and there were fewer peaks during sleep.
Keywords: intraocular pressure, 24-hour, normal tension glaucoma
Background
Intraocular pressure (IOP) is one the most important modifiable risk factors for 
glaucoma progression.1–3 IOP measurements in the ophthalmology clinic are often 
limited to office hours, which do not fully represent the nychthemeral IOP peaks and 
fluctuations.4,5 Previously, 24-hour IOP monitoring studies have reported fluctuation 
as high as 8.2±1.4 mmHg, but many of these studies measured IOP in the sitting 
position, overnight in a hospital environment, and over a few sampling periods, 
which does not truly reflect the physiological and normal setting of one’s daily living, 
especially when the subjects are awakened at night for IOP measurements.6–10
Various studies have reported the significance of IOP fluctuation on glaucoma 
progression.11,12 While there are studies that report otherwise,13,14 much of the existing 
literature has only documented inter-visit or daytime IOP variability over a limited 
number of hours. This is at least partly due to limitations of how frequently repeated 
tonometric IOP measurements can be taken.
A contact lens-based sensor (CLS) is nowadays available for the recording of ocular 
dimensional profiles for up to 24 hours.15 This device has been shown to be safe and 
tolerable in healthy subjects and glaucoma patients as well as to provide reproducible 
recording of 24-hour profiles.16–18
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The aim of this study was to analyze the 24-hour ocular 
dimensional profile in normal-tension glaucoma (NTG) 
patients on medical treatment.
Methods
This study adhered to the tenets of the Declaration of Hel-
sinki. Informed patient consent and approval by the Institu-
tional Review Board of the Hospital Authority of Hong Kong 
were obtained prior to study commencement.
This was a prospective cohort study from July 2012 to 
June 2013, conducted at a university hospital in Hong Kong. 
The study recruited consenting adults (age 18 years old) 
with unilateral or bilateral NTG who were currently on 
topical antiglaucoma medications. NTG was defined as open 
angle on gonioscopy; progressive thinning of the retinal 
nerve fiber layer (RNFL) on optical coherence tomography, 
with corresponding glaucomatous visual field changes on the 
Humphrey Visual Field Analyzer; and an IOP 21 mmHg 
on all clinical visits based on previous medical records. 
Cases with previous glaucoma surgery or laser treatment, 
active or previous corneal disease, and subjects with only 
one functional eye were excluded.
The SENSIMED Triggerfish® (Sensimed AG, Lausanne, 
Switzerland) is a soft silicone CLS that enables recording 
of the ocular dimensional profile over a 24-hour period 
with minimal disturbance to one’s daily routines and sleep 
cycles. Such 24-hour profiles are related to the 24-hour 
IOP profiles.18 Dimensional changes are recorded in the 
corneoscleral area for 30 seconds every 5 minutes over 
24 hours and each recording “burst” represents 300 data 
points, the medians of which are plotted as a single graph 
which makes up the 24-hour ocular dimensional profile 
measured in sensory output units of millivolt equivalents 
(mVeq). The device was CE-marked and thus approved for 
clinical use in 2009. In healthy volunteers and glaucoma 
patients, the CLS was found to be tolerable in normal activi-
ties of daily living and during sleep. A contact lens with base 
curve 8.7 mm was also found to be well adapted in most eyes, 
although the device also exists in steeper (8.4 mm) and flatter 
(9.0 mm) base curves.16–18
The CLS was placed on the subject’s eye by an ophthal-
mologist in the outpatient clinic after a slit-lamp examination 
of the anterior segment and Goldmann applanation tonometry 
(GAT) by a single investigator. For those with unilateral 
disease, the CLS was placed on the eye with NTG. For those 
with bilateral disease, a random eye assignment by card shuf-
fling was used to determine the eye for the CLS placement. 
The subject then returned home with lubricating eyedrops 
and carried on his or her daily activities (both indoor and 
outdoor), apart from showering or swimming (as the device 
cannot be in contact with water). Subjects continued their 
same regimen of antiglaucoma eyedrops and slept in their 
habitual position at night. Each subject carried a logbook 
to record sleeping times during the 24-hour period. After 
24 hours, the subject returned to the clinic to have the CLS 
removed followed by a slit-lamp examination and GAT. The 
data recorded by the SENSIMED Triggerfish® device were 
uploaded into a computer database. CLS profile parameters 
were extracted following smoothing of the profile using 
locally weighted polynomial regression.
Definitions
•	 CLS variability from mean: this variable reflects vari-
ability around the mean value of all raw (not smoothed) 
CLS measurements in the respective period (24-hour, 
diurnal, or nocturnal).
•	 Diurnal/nocturnal variability: same as above but only 
during the awake and asleep periods, respectively, where 
the sleep cycle is determined from recorded sleep times in 
each individual’s logbook and verified by the eye-blinking 
frequency (present during waking) and the presence of 
rhythmic ocular pulsation waves (present during sleep).
•	 Sleep-to-wake and wake-to-sleep slopes: calculated with 
a generalized linear model on raw measurements in units 
of mVeq/hour from 1 hour before sleep or wake time to 
1 hour after sleep or wake time, respectively.
•	 Number of peaks: a peak is defined as a local maximum 
point in the smoothed curve. The calculation of the num-
ber of peaks occurs as follows: each trough is noted as 
the start of a peak.
statistical analysis
The pre- and post-CLS GAT IOPs were compared using 
the Wilcoxon signed-rank test. The following parameters, 
extracted from CLS profiles, were compared using the 
Mann–Whitney U-test:
1. nocturnal versus diurnal mean variability from mean;
2. wake-to-sleep versus sleep-to-wake slopes;
3. number of nocturnal versus diurnal peaks; and
4. 24-hour, diurnal, and nocturnal variability among pros-
taglandin users and nonusers.
Fisher’s exact test was used to compare the differences in 
the number of nocturnal peaks between those using a prosta-
glandin antiglaucoma medication versus those using other, 
non-prostaglandin antiglaucoma medications. Statistical 
significance was taken as P0.05.
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Results
In the 18 subjects enrolled in the study, there were seven 
males and eleven females. The mean age was 65.1±13.7 years. 
GAT IOPs before and after the CLS wear were 15.3±2.2 
and 13.8±1.7 mmHg, respectively, while on the same 
antiglaucoma medications (P=0.05). The mean RNFL 
thickness was 72.9±9.8 µm and the mean deviation and pat-
tern standard deviation on Humphrey visual field analysis 
were -6.3±4.5 decibels (dB) and 6.1±4.1 dB, respectively.
The mean number of antiglaucoma eyedrops was 1.7±0.7. 
In the 18 subjects, 38.9% (7/18) used a single prostaglandin 
eyedrop administered in the evening, 44.4% (8/18) used a 
twice-daily non-prostaglandin eyedrop, and 17.6% (3/17) 
used both a nocturnal prostaglandin eyedrop plus a twice-
daily antiglaucoma eyedrop.
The mean 24-hour variability from the mean CLS signal 
was 75.9±21.5 (range: 35.7–120.9; 95% confidence interval 
[CI]: 62.8–86.7) mVeq. The mean nocturnal variability 
from the mean was 52.1±20.3 (range: 23.9–105.1; 95% CI: 
41.6–62.5) mVeq, which was 48.9% less than the mean diur-
nal variability from the mean (77.6±20.6) (range: 43.9–118.4; 
95% CI: 66.9–88.2) mVeq (P=0.002). There were no statisti-
cally significant differences in the mean diurnal, nocturnal, 
or 24-hour variability between those with and without pros-
taglandin analog treatment (all P0.1) (Table 1).
The mean number of peaks during sleep and daytime was 
6.4±2.3 and 9.3±2.4, respectively. The number of peaks was 
54.7% less during the nocturnal period than the diurnal period 
(P=0.001). There was no significant difference between the 
frequencies of nocturnal peaks among those using a prosta-
glandin antiglaucoma medication versus those using other, 
non-prostaglandin antiglaucoma medications (Table 2).
The mean sleep time of subjects was from 8.53 pm ±12.6 
minutes to 7.06 am ±3.6 minutes. The study popula-
tion had a mean positive linear slope on their CLS 
profile from wake-to-sleep with a mean of 53.2±42.9 
mVeq/hour, signifying an increase in the ocular dimen-
sional profile when going to sleep. Similarly, the popula-
tion had a mean negative linear slope from sleep-to-wake 
with a mean of -42.5±47.6 mVeq/hour, signifying a 
decrease in the ocular dimensional profile upon waking. 
On comparing the two slopes, the rate of increase when going 
to sleep was significantly greater than the rate of decrease 
upon waking (P0.001) (Table 3).
Discussion
The ocular dimensional profiles of all 18 NTG subjects were 
unique, with individual peaks occurring at different time 
intervals throughout the day and night; no two tracings were 
identical. The mean ocular dimensional profile of the study 
population increased during sleep (positive wake-to-sleep 
slope) and decreased upon waking (negative sleep-to-wake 
slope), with the mean rate of increase during sleep being 
significantly greater than the rate of decrease upon waking 
(P0.001). We are inclined to agree with previous postulations, 
wherein the increase in nocturnal IOP was thought to be related 
to the gravitational pull of fluids to the eye and an increase in 
episcleral venous pressure during the supine sleep posture.19 
Through the use of the 24-hour CLS, we affirm that the phe-
nomenon of increased IOP with supine posturing was consistent 
among NTG subjects under medical treatment. Other authors 
have also observed the persistence of posture-induced IOP 
changes despite treatment of NTG patients with IOP-lowering 
medication.20 Similarly, a previous Japanese study reported, in a 
population of NTG subjects, that the IOP spikes recorded from 
the habitual positions (sitting up during the day and supine at 
night) were positively correlated to the spikes induced from a 
postural-change test and after a water-drinking test.21 In con-
trast, Renard et al reported that, in 27 subjects with suspected 
NTG, 24-hour IOP monitoring revealed that 54.5% exhibited a 
diurnal acrophase and 36.4% exhibited a nocturnal acrophase, 
while 9.1% had no nychthemeral rhythm in the absence of 
medical treatment.22 The existence of concomitant obstructive 
sleep apnea syndrome in 80% of assessed patients could have 
influenced the observed IOP rhythm in their cohort.22
Before the availability of continuous 24-hour ocular 
dimensional profile recording, it has been reported that, in 
many glaucoma patients, the IOP peaks occurred outside of 
office hours23,24 and that two-thirds of IOP peaks in untreated 
glaucoma patients occurred during the nocturnal period.25 
Table 1 Mean 24-hour, diurnal, and nocturnal variability among subjects with and without prostaglandin analog treatment
Subjects on prostaglandin  
analogs (n=9)
Subjects not on prostaglandin  
analogs (n=8)
P-value
Mean 24-hour variability (mVeq) 84.8±20.3 71.1±17.2 0.1
Mean diurnal variability (mVeq) 85.4±22.3 68.7±15.4 0.1
Mean nocturnal variability (mVeq) 47.2±13.2 57.5±26.0 0.7
Note: sleep data are missing for subject 18, thus, this subject’s data was not included in the variability calculations.
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In our NTG population, we noted that there were 55% less 
peaks occurring nocturnally than diurnally (P=0.001). The 
reduction in the number of peaks at night in our NTG popu-
lation could be related to the use of prostaglandin antiglau-
coma eyedrops, since 57% of our subjects were at least on 
prostaglandin antiglaucoma eyedrops nocturnally. However, 
it may also be simply due to the absence of physical activ-
ity, eye blinking, and saccadic movements at night, as these 
parameters are known to cause IOP spikes and fluctuations.26 
Other authors have suggested that the nocturnal IOP and 
IOP spikes may be related to visual field progression in 
NTG subjects.21
Study on the effect of medical treatment on IOP fluctua-
tions has shown that prostaglandin antiglaucoma eyedrops 
offer the best sustained 24-hour IOP reduction, while bri-
monidine offers the least.27 In our study, the mean nocturnal 
variability was significantly lower than the mean diurnal vari-
ability by 49% (P=0.002). Our findings are in agreement with 
a previous study by Pajic et al28 reporting higher coefficients 
of variation in CLS data during the daytime than at nighttime 
in NTG patients. Pajic et al reported reduced variability in 
nocturnal CLS data independent of whether or not patients 
were on antiglaucoma medication.28 We have not recorded 
CLS profiles in our patients without medical treatment and 
therefore do not know whether the same is valid for this 
patient cohort; however, it seems plausible that the lower 
level of activity during sleep provides a natural reduction 
in variability, which IOP-lowering medical treatment may 
further influence. Holló et al recorded CLS profiles in primary 
open-angle glaucoma and ocular hypertension patients and 
found no difference in 24-hour, diurnal, or nocturnal standard 
deviation of CLS values in the presence of prostaglandin 
analog treatment as compared to without treatment.29 The 
variability of diurnal versus nocturnal CLS values was not 
evaluated. Thus, in this patient cohort, it seems that, while 
the overall ocular dimensional profile was higher at night, 
the number of peaks and variability from the mean were 
significantly reduced at night for NTG subjects on medical 
treatment. The use of prostaglandins did not significantly 
affect the CLS variability (P0.1).
It was interesting to note that the GAT IOP after CLS wear 
(13.8±1.7 mmHg) was lower (P=0.05) than the IOP before 
the CLS wear (15.3±2.2 mmHg), although the readings were 
measured exactly 24 hours apart. This seemingly lower IOP 
after the CLS use was short of statistical significance and can 
be explained by day-to-day variations in IOP.
There were limitations in this study. There was no sample 
size calculation, and the relatively small sample size of the 
study did not allow for evaluation of differences in IOP-
related pattern nor stratification by the type of treatment. 
Furthermore, only one 24-hour measurement with the CLS 
was performed, therefore we could not ascertain the repro-
ducibility of the 24-hour IOP profile. At present, the ocular 
dimensional profile is something that cannot be translated 
Table 2 Frequency distribution of number of peaks during the nocturnal period in subjects with and without prostaglandin treatment
Number of peaks during  
the nocturnal period
Patients treated with prostaglandins All P-value for comparison 
between prostaglandin 
groups
Yes No
N % N % N %
5 0 0 1 11.1 1 5.9
6 1 12.5 1 11.1 2 11.8
7 0 0 1 11.1 1 5.9
8 0 0 1 11.1 1 5.9
9 3 37.5 1 11.1 4 23.5
10 1 12.5 3 33.3 4 23.5
11 1 12.5 0 0 1 5.9
13 2 25.0 1 11.1 3 17.6
all 8 100.0 9 100.0 17 100.0 0.7
Note: sleep data are missing for subject 18, thus the number of peaks during the nocturnal period could not be calculated for this subject.
Table 3 SENSIMED Triggerfish® contact lens-based sensor 24-hour parameters in diurnal versus nocturnal periods
Diurnal Nocturnal P-value
Variability (mVeq) 77.6±20.6 52.1±20.3 0.002*
Peaks (number) 9.3±2.4 6.4±2.3 0.001*
slopes (mVeq/hour) 53.2±42.9 (wake-to-sleep) -42.5±47.6 (wake-to-sleep) 0.001*
Note: *Statistically significant.
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into IOP and therefore has no validation for use in clinical 
practice. Additional clinical research needs to be done before 
we can state (based on evidence) that the CLS can be useful 
in optimizing the timing of medical therapy for individual 
patients. Nevertheless, this is one of the few publications 
in the literature analyzing the 24-hour ocular dimensional 
profile on a continuous basis in NTG subjects receiving 
medical treatment.
Conclusion
Continuous 24-hour ocular dimensional profiles recorded 
in NTG patients on medical treatment revealed that the 
profile increased during sleep and decreased upon waking. 
There was a 50% reduction in both the variability from the 
mean and number of peaks during sleep as compared to 
daytime.
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